10 gynecological Chinese patent medicines "big sell" 9 exclusive varieties Baping

The latest data from Mi Nei.
com shows that in the first half of 2021, China's public medical institutions' terminal gynecological Chinese patent medicine market sales increased by 5.
80% year-on-year
.
From the perspective of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical are still in the top five
.
Nine of the TOP10 products are exclusive.
Baofukang Suppository, Gynecological Qianjin Capsule, and Kuntai Capsule are among the top three; in terms of growth rate, Baofukang Suppository, Zishen Yutaiwan and other three products are all over 30% , Only beneficial mother grass injection is negative growth
.
Since 2019, only one Chinese patent medicine for gynecology has been approved for listing.
In addition, Kunyining Granules of Tasly Pharmaceutical Group are under review and approval, Qiling Wenshen Xiaonang Granules of Tasly Pharmaceutical Group, Jiangxi Baishenchang Five new drugs including Gongyankang Gel from Nuo Pharmaceutical and Guangfangfeng Capsule from Shanghai Pharmaceutical Port Biotechnology have been approved for clinical use
.
Policy dividends followed one after another.
Tasly's new class 1 medicines "struck".
In February this year, the State Council issued the "Policies and Measures for Accelerating the Development of Traditional Chinese Medicine", which clearly stated that it is necessary to improve the vitality of the development of the Chinese medicine industry and optimize the management of Chinese medicine review and approval.
Improve the classification and registration management of traditional Chinese medicine; In June, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly formulated the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine"; in July, the National Development and Reform Commission and other four departments issued the "" The 14th Five-Year Plan for the Construction of High-quality and Efficient Medical and Health Service System; In October, the National Health Commission issued the "Mother and Child Safety Action Improvement Plan (2021-2025)", proposing to promote traditional Chinese medicine services, obstetrics and gynecology, and pediatrics were active Apply the appropriate technology of Chinese medicine to give full play to the unique role of Chinese medicine in the prevention and health of women and children and the diagnosis and treatment of diseases.
Maternal and child health institutions at all levels provide comprehensive Chinese medicine services to make Chinese medicine gynecology, Chinese medicine pediatrics and other specialties better and stronger.
.
.
In the field of Chinese medicine, a series of related policies have been implemented and promoted, and the status of Chinese medicine has been continuously improved
.
Source of gynecological Chinese patent medicines declared for listing/clinical since 2019: Meinenet MED2.
0 Chinese drug review database Since 2019, only Guangzhou Kangyuan Pharmaceutical’s Jinrong Xiaopi Granules have been approved as new drugs in category 6.
1 , This variety is a traditional Chinese medicine compound preparation for the treatment of breast hyperplasia
.
At present, the Kunyining granules of Tasly Pharmaceutical Group has submitted a marketing application and is under review and approval.
The product is an innovative Chinese medicine for the treatment of female menopausal syndrome
.
In addition, five new drugs including Qiling Wenshen Xiaosang Granules from Tasly Pharmaceutical Group, Gongyankang Gel from Jiangxi Baishen Changnuo Pharmaceutical, and Guangfangfeng Capsules from Shanghai Yaogang Biotechnology have been approved for clinical use
.
Thousands of dollars and step lengths "lead" the tens of billions market in recent years.
The sales situation of Chinese public medical institutions' terminal gynecological Chinese patent medicines in recent years.
Source: China's public medical institutions' terminal competition pattern.
The market size of terminal gynecological Chinese patent medicines in community centers and township health centers (Chinese public medical institutions) exceeds 10 billion yuan.
Sales affected by the epidemic in 2020 will decline year-on-year, and will return to growth in the first half of 2021.
Urban public hospitals and county-level hospitals Public hospitals are the main sales channel, with a total market share of over 85%
.
In terms of quarterly sales, the growth rate in the first quarter of 2021 will exceed 20%
.
Among the 6 sub-categories of gynecological Chinese patent medicines, gynecological inflammation medications and gynecological menstruation regulating drugs are still the two most popular subcategories, with a combined market share of more than 65%
.
It is worth noting that the women's menopausal medication market has maintained steady growth in recent years.
In the first half of this year, sales increased by nearly 30% year-on-year.
It is also the only subcategory that has experienced positive growth for three consecutive years
.
2021H1 China's public medical institutions terminal gynecological proprietary Chinese medicine manufacturers TOP3 Source: China's public medical institutions terminal competition pattern from the perspective of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, Jiangsu Kangyuan Pharmaceutical ranks in the top five, with a total market share of more than 25%
.
TOP10 Gynecological Chinese Patent Medicines "Great Counterattack"! Nine exclusive products dominate the screen, only one with negative growth.
China's public medical institutions' terminal gynecological Chinese patent medicine products TOP10 Source: China's public medical institutions' terminal competition pattern The sales of TOP10 products all exceeded 100 million yuan
.
Among them, Baofukang Suppository, Gynecological Qianjin Capsule, and Kuntai Capsule are among the top three
.
It is worth mentioning that, except for Honghua Xiaoyao tablets in the TOP10 products, the other 9 are exclusive products, involving Hainan Bikai Pharmaceutical, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Jiangsu Kangyuan Pharmaceutical and other companies
.
Baofukang Suppository is the exclusive product of Hainan Bikai Pharmaceutical, and it is the world's first traditional Chinese medicine suppository for the treatment of HPV infection and prevention of cervical cancer
.
According to data from Mi Nei.
com, in recent years, the sales of terminal Bao Fu Kang Suppository in public medical institutions in China have grown steadily.
In 2020, due to the impact of the epidemic, there will be a slight decline and a year-on-year growth of more than 40% in the first half of this year
.
Gynecological Qianjin Capsule is the exclusive product of Zhuzhou Qianjin Pharmaceutical.
According to data from Minai.
com, the market share of Gynecological Qianjin Capsules in China's public medical institutions has steadily increased in recent years.
In the first half of 2021, the market share reached 3.
69%, and sales increased by more than 15% year-on-year
.
Qianjin Pharmaceutical pointed out in the semi-annual report that with the advancement of the national basic drug policy, the company implemented the marketing strategy of "fundamental drug development", focusing on promoting the two exclusive basic drug products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules Under the influence of the epidemic, the medical sector will still maintain a certain share of growth in the first half of 2021
.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years
.
In the first half of this year, Gynecological Qianjin Capsule was approved by the Pakistan Drug Administration for its innovative Chinese patent medicine.
This is the first overseas clinical trial approval by Qianjin Pharmaceutical
.
Kuntai Capsule is the only Chinese patent medicine to improve ovarian function, and it is the exclusive product of Guiyang Xintian Pharmaceutical
.
According to data from Meinenet, in 2020, Kuntai Capsules in China's public medical institutions will be promoted to the TOP3 product list, with a year-on-year growth of more than 30% in the first half of this year
.
Xintian Pharmaceutical said that Kuntai capsule is one of the main varieties that will develop rapidly in the future.
The company will further optimize the industrial layout based on the existing advantages, especially in women’s youth and health maintenance, men’s health, Market segment products such as reproductive system diseases have realized the linkage development pattern of a series of product lines
.
In terms of growth rate, Baofukang Suppository, Kuntai Capsule, and Zishen Yutai Pills all exceeded 30%, and only beneficial mother grass injection was a negative growth; from the perspective of treatment categories, gynecological inflammation drugs accounted for half of the country, with five
.
Source: Mi Nei.
com database, company announcement